Drug General Information
Drug ID	D0H3UO
Former ID	DIB005488
Drug Name	RGD-039
Synonyms	N-Ethyl-N-[4-(4-piperidyl)butyryl]-glycyl-L-aspartyl-L-(3-cyclohexyl)alanine
Indication	Thrombosis [ICD9: 437.6, 453, 671.5, 671.9; ICD10:I80-I82]		Investigative	[525886], [525902]
Structure		Download 2D MOL
Target and Pathway
Target(s)	Glycoprotein IIb/IIIa receptor	Target Info	Modulator	[525886], [525902]
Reactome	Platelet degranulation
	Elastic fibre formation
	PECAM1 interactions
	Molecules associated with elastic fibres
	Integrin cell surface interactions
	Syndecan interactions
	ECM proteoglycans
	Integrin alphaIIb beta3 signaling
	GRB2:SOS provides linkage to MAPK signaling for Integrins
	p130Cas linkage to MAPK signaling for integrins
	VEGFA-VEGFR2 Pathway
	MAP2K and MAPK activation
WikiPathways	Focal Adhesion
	Hematopoietic Stem Cell Differentiation
	Human Complement System
	Extracellular matrix organization
	Arrhythmogenic Right Ventricular Cardiomyopathy
	Integrin-mediated Cell Adhesion
	L1CAM interactions
	Integrin cell surface interactions
	Integrin alphaIIb beta3 signaling
References
Ref 525886	Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM). J Clin Pharmacol. 2000 Oct;40(10):1129-40.
Ref 525902	Pharmacokinetics, pharmacodynamics, and safety of a platelet GPIIb/IIIa antagonist, RGD891, following intravenous administration in healthy male volunteers. J Clin Pharmacol. 2000 Nov;40(11):1245-56.
Ref 525886	Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM). J Clin Pharmacol. 2000 Oct;40(10):1129-40.
Ref 525902	Pharmacokinetics, pharmacodynamics, and safety of a platelet GPIIb/IIIa antagonist, RGD891, following intravenous administration in healthy male volunteers. J Clin Pharmacol. 2000 Nov;40(11):1245-56.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.